W. Pan - 2Center for Observation and Real-World Evidence, Merck & Co., Inc

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 59 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract PS14-05: Safety Evaluation from the KEYNOTE-522 Study of Neoadjuvant Pembrolizumab (or Placebo) Plus Chemotherapy Followed by Adjuvant Pembrolizumab (or Placebo) in Patients with Early Triple-Negative Breast Cancer (TNBC)

Javier Cortés,Rebecca Dent,Lajos Pusztai,Heather McArthur,Sherko Kuemmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Masato Takahashi,Carlos Barrios,Yalin Zhu, Xiaoli Zhang,Wilbur Pan,Vassiliki Karantza,Joyce O'Shaughnessy,Peter Schmid

Cancer Researchno. 9_Supplement (2024): PS14-05

引用0浏览0引用

Neoadjuvant Pembrolizumab Plus Chemotherapy/adjuvant Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: Quality-of-life Results from the Randomized KEYNOTE-522 Study

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTEno. 10 (2024): 1654-1663

引用0浏览0WOS引用

Association Between Event-Free Survival and Overall Survival in Early-Stage Triple-Negative Breast Cancer

Min Huang,Peter A. Fasching,Amin Haiderali,Weiguang Xue,Wilbur Pan, Vassiliki Karantza,Fan Yang,James E. Truscott, Yiqiao Xin,Joyce O’Shaughnessy

Future oncology（2024）

引用0浏览0引用

Positive 52-Week Maintenance Data Observed with Rademikibart in Patients with Moderate-to-severe Atopic Dermatitis (SEASIDE CHINA)

Jianzhong Zhang,Jonathan Silverberg, Jiawang Guo, Jili Yun,Wuban Pan, Zheng Wei,Raul Collazo

BRITISH JOURNAL OF DERMATOLOGY (2024)

引用0浏览0引用

Abstract PS14-08: Safety Evaluation from the KEYNOTE-355 Study of Pembrolizumab Plus Chemotherapy Vs Placebo Plus Chemotherapy in Patients with Previously Untreated, Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer

Hope Rugo,Peter Schmid,Zbigniew Nowecki,David Cescon,Seock-Ah Im, Mastura Yusof,Carlos Gallardo,Hiroji Iwata,Carlos Barrios,Sherene Loi,Xuan Zhou, Xiaoli Zhang,Wilbur Pan,Vassiliki Karantza,Javier Cortés

Cancer Researchno. 9_Supplement (2024): PS14-08

引用0浏览0引用

Icanbelimod (CBP-307), a Next-Generation Sphingosine-1-phosphate Receptor Modulator, in Healthy Men: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in a Randomized Trial in Australia

Jason Lickliter, Xin Yang, Jiawang Guo,Wubin Pan, Zheng Wei

FRONTIERS IN IMMUNOLOGY（2024）

引用0浏览0WOS引用

Efficacy and Safety of Rademikibart (CBP-201), a Next-Generation Mab Targeting IL-4Rα, in Adults with Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Trial (CBP-201-WW001)

Jonathan I. Silverberg,Bruce Strober, Brian Feinstein,Jinhua Xu,Emma Guttman-Yassky,Eric L. Simpson,Pauline Li,Malinda Longphre, Jing Song, Jiawang Guo, Jang Yun,Belinda Williams,Wubin Pan,Selwyn Ho,Raul Collazo, Zheng Wei

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYno. 4 (2024)

引用3浏览0WOS引用

IL-36 Regulates Neutrophil Chemotaxis and Bone Loss at the Oral Barrier

J. Liu, H. Meng, Y. Mao, L. Zhong,W. Pan,Q. Chen

JOURNAL OF DENTAL RESEARCHno. 4 (2024): 442-451

引用0浏览0WOS引用

Event-free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage TNBC: Exploratory Analysis from KEYNOTE-522

L Pusztai,C Denkert,J O'Shaughnessy, J Cortes,R Dent,H McArthur,S Kümmel,J Bergh,Y H Park,R Hui,N Harbeck, M Takahashi,M Untch,P A Fasching,F Cardoso, Y Zhu,W Pan,K Tryfonidis, P Schmid

Annals of oncology official journal of the European Society for Medical Oncology（2024）

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn